1. Home
  2. SABR vs AVDL Comparison

SABR vs AVDL Comparison

Compare SABR & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABR
  • AVDL
  • Stock Information
  • Founded
  • SABR 2006
  • AVDL 2015
  • Country
  • SABR United States
  • AVDL Ireland
  • Employees
  • SABR N/A
  • AVDL N/A
  • Industry
  • SABR Computer Software: Programming Data Processing
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SABR Technology
  • AVDL Health Care
  • Exchange
  • SABR Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • SABR 1.2B
  • AVDL 1.4B
  • IPO Year
  • SABR 2014
  • AVDL 1996
  • Fundamental
  • Price
  • SABR $1.86
  • AVDL $15.41
  • Analyst Decision
  • SABR Buy
  • AVDL Strong Buy
  • Analyst Count
  • SABR 5
  • AVDL 8
  • Target Price
  • SABR $4.12
  • AVDL $20.88
  • AVG Volume (30 Days)
  • SABR 6.0M
  • AVDL 1.4M
  • Earning Date
  • SABR 10-30-2025
  • AVDL 11-11-2025
  • Dividend Yield
  • SABR N/A
  • AVDL N/A
  • EPS Growth
  • SABR N/A
  • AVDL N/A
  • EPS
  • SABR N/A
  • AVDL N/A
  • Revenue
  • SABR $3,010,157,000.00
  • AVDL $221,075,000.00
  • Revenue This Year
  • SABR N/A
  • AVDL $63.77
  • Revenue Next Year
  • SABR $4.17
  • AVDL $29.91
  • P/E Ratio
  • SABR N/A
  • AVDL N/A
  • Revenue Growth
  • SABR 6.13
  • AVDL 132.35
  • 52 Week Low
  • SABR $1.69
  • AVDL $6.38
  • 52 Week High
  • SABR $4.63
  • AVDL $16.66
  • Technical
  • Relative Strength Index (RSI)
  • SABR 50.34
  • AVDL 63.26
  • Support Level
  • SABR N/A
  • AVDL $14.78
  • Resistance Level
  • SABR $1.83
  • AVDL $16.04
  • Average True Range (ATR)
  • SABR 0.07
  • AVDL 0.55
  • MACD
  • SABR -0.01
  • AVDL -0.12
  • Stochastic Oscillator
  • SABR 95.63
  • AVDL 65.57

About SABR Sabre Corporation

Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: